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In vitro Activity of Tigecycline, a New Glycylcycline, Tested Against 1,326
Clinical Bacterial Strains Isolated from Latin America
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Andrea S. Pereira1 and Hélio S. Sader2 Infectious Diseases1, Department of Medicine, São
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The in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was
evaluated in comparison with tetracycline and other antimicrobial agents. Material and Methods:
A total of 1,326 contemporary clinical isolates collected from the Latin American region were
collected in 2000-2002 period and tested with microdilution broth according to the CLSI guidelines.
The bacterial pathogens evaluated included Staphylococcus aureus (505), Streptococcus
pneumoniae (269), coagulase-negative staphylococci (CoNS; 227), Haemophilus influenzae (129),
Enterococcus spp. (80), Moraxella catarrhalis (54), β-haemolytic streptococci (28), viridans
group streptococci (26), and Neisseria meningitidis (8) Results: Tigecycline demonstrated
excellent activity against all Gram-positive cocci, with 90% of penicillin-resistant S. pneumoniae
strains being inhibited at 0.12 µg/mL, while the same isolates had an MIC90 of > 16 µg/mL for
tetracycline. All Enterococcus spp. were inhibited at 0.25 µg/mL of tigecycline. Tigecycline
(MIC50, 0.25 µg/mL) was eight-fold more potent than minocycline (MIC50, 2 µg/mL) against
oxacillin-resistant S. aureus (ORSA); all ORSA were inhibited at ≤ 2 µg/mL of tigecycline.
Tigecycline demonstrated excellent activity (MIC50, 0.5 µg/mL) against CoNS with reduced
susceptibility to teicoplanin (MIC, 16 µg/mL). Tigecycline also showed high potency against
respiratory pathogens such as M. catarrhalis (MIC50, 0.12 µg/mL) and H. influenzae (MIC50, 0.5
µg/mL). No tigecycline resistant isolates were detected when the proposed susceptible breakpoints
(≤ 4 µg/mL) was applied. Conclusions: This results indicate that tigecycline has potent in vitro
activity against clinically important pathogenic bacteria, including Gram-positive isolates resistant
to both tetracycline and minocycline.
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The tetracyclines have been widely used during in
last four decades, due to their broad-spectrum of
antimicrobial activity against Gram-positive and Gram-
negative aerobic bacteria, including many intracellular
pathogens and anaerobic organisms [1,2]. However,
indications for the use of tetracyclines have been limited
to specific clinical indications, due to the emergence of
resistant strains in frequently isolated species, such as
Staphylococcus aureus, Enterococcus spp.,
Streptococcus pneumoniae, and Neisseria
gonorrhoeae [1-4].
Tigecycline, former GAR-936, is the first
representative of a new class of antimicrobial agents
known as glycylcyclines. This compound is a
semisynthetic 9-t-butylglycylamido derivative of the
minocycline molecule [5]. Although tigecycline acts on
the bacterial ribosome by binding sites similar to those
of tetracycline, the radical added to position 9 of the
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tigecycline molecule has provided additional steric
hindrance features that result in a greater spectrum of
activity [6]. Thus, tigecycline has documented activity
against tetracycline-resistant (tet-R) Gram-positive and
Gram-negative pathogens, refractory to both efflux and
ribosomal protection mechanisms [7].
Our main objective was to evaluate the in vitro
activity of tigecycline in comparison to tetracycline and
other antimicrobial agents against clinical bacterial
isolates recently collected from Latin American medical
centers.
Material and Methods
Organisms
A total of 1,326 clinical bacterial isolates collected
from the Latin American region in 2000-2002 period
were evaluated. The distribution of species was as
following as: Staphylococcus aureus (505 strains),
Streptococcus pneumoniae (269 strains), coagulase
negative staphylococci (227 strains), Haemophilus
influenzae (129 strains), Enterococcus spp. (80
strains), β-haemolytic streptococci (28 strains), viridans
group streptococci (26 strains), Moraxella catarrhalis
(54 strains), and Neisseria meningitides (8 strains).
Only a single isolate per patient was evaluated. The
isolates were identified to the species level by the
participating medical center, and sent to the coordinating
laboratory for identification confirmation and reference
susceptibility testing.
Medical centers
Clinical isolates of facultatively aerobic bacteria
were collected in 11 Latin American laboratories
distributed throughout 10 cities (six countries): São
Paulo, Florianópolis, Porto Alegre and Brasília (only
2002), Brazil; Buenos Aires and San Isidro, Argentina;
Santiago (two centers), Chile; Medellin, Colombia
(only 2000); Caracas, Venezuela; and Mexico City,
Mexico. The selection of participating centers was
based on the principle that they should be sentinels in
their respective geographic region. The participating
medical centers were directed by a protocol to collect
isolates from consecutive patients from specific sites
of infections, including bloodstream infections,
community-acquired respiratory infections,
pneumonia in hospitalized patients, and skin and soft
tissue infections.
Susceptibility testing
Antimicrobial susceptibility testing was performed
using broth microdilution methods, as described by the
Clinical Laboratory Standard Institute (CLSI, formerly
NCCLS) [8]. Antimicrobial agents were obtained from
their respective manufacturers as laboratory grade
powder. Minimal inhibitory concentrations (MICs)
results were interpreted according to NCCLS
breakpoints [9]. A tigecycline susceptible breakpoint
of <4 µg/mL for staphylococci and enterococci, and ≤
2 µg/mL for other pathogens were used for comparative
purposes only. Quality control measures were utilized
by testing S. pneumoniae ATCC 49619, S. aureus
ATCC 29213, Enterococcus faecalis ATCC 29212,
Escherichia coli ATCC 25922, and Pseudomonas
aeruginosa ATCC 27853.
Results
The largest number of isolates was collected from
the Brazilian medical centers (573 isolates, 43.2%),
followed by the Chilean (377 isolates, 28.4%) and
Argentinean (264 isolates, 19.9%) medical centers.
These three countries contributed with >90% of isolates
(Table 1). Species tested in rank order of frequency
were as follows: S. aureus (42.9% oxacillin-resistant);
S. pneumoniae (27.1% penicillin-non-susceptible),
CoNS (79.3% oxacillin-resistant), H. influenzae
(17.8% β-lactamase-producers), Enterococcus spp.
(10.3% vancomycin-resistant), M. catarrhalis (92.6%
β-lactamase-producers), β-haemolytic streptococci
(34.6% erythromycin-non-susceptible), viridans group
streptococci (30.8% penicillin-non-susceptible), and
Neisseria meningitides.
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The antimicrobial activity of tigecycline was compared
to selected antimicrobial agents (Table 2). Tigecycline
was highly active against both oxacillin-resistant and –
susceptible S. aureus (MIC50, 0.25 µg/mL and MIC90,
0.5 µg/mL for both groups). More than 99% of the strains
were inhibited at <0.5 µg/mL of tigecycline. Similarly to
S. aureus, both oxacillin-resistant and -susceptible
coagulase-negative staphylococci were very susceptible
to tigeclycline (MIC50, 0.25 µg/mL and MIC90, 0.5 µg/
mL for both). Vancomycin and linezolid were the only
antimicrobial agents active against all staphylococcal
strains at the susceptible breakpoint. Tigecycline (MIC50,
0.25 µg/mL) was at least four-fold more potent than
vancomycin (MIC50, 1 µg/mL) or linezolid (MIC50, 1-2
µg/mL) against oxacillin-resistant staphylococci.
Tigecycline was also highly active against tetracycline-
resistant staphylococci. Co-resistance among
tetracycline, erythromycin, and fluoroquinolones was
noticed within the subsets of oxacillin-resistant
staphylococci and did not affect tigecycline in vitro
activity against staphylococci.
Although tigecycline and linezolid inhibited 100%
of the Enterococcus spp. strains tested, tigecycline
(MIC50, 0.25 µg/mL) was eight-fold more potent than
linezolid (MIC50, 2 µg/mL). The vast majority of
Enterococcus spp. were susceptible to ampicillin
(MIC50, ≤ 1 µg/mL; 88.8% susceptible) and resistant
to quinupristin/dalfopristin (MIC50, 8 µg/mL; 13.8%
susceptible), reflecting the preponderance of E.
faecalis in the collection. Tigecycline showed excellent
potency against both vancomycin- and tetracycline-
resistant Enterococcus spp.
Table 1. Frequency of pathogens tested for tigecycline susceptibility according to the country of isolation (SENTRY
Antimicrobial Surveillance Program, Latin America, 2000-2002)
Country
Organism Argentina Brazil Chile Colombia Mexico Venezuela Total (%)
Staphylococcus aureus
Oxacillin-susceptible 53 144 63 7 5 16 288 (21.7)
Oxacillin-resistant 37 108 68 1 1 2 217 (16.3)
CoNSa
Oxacillin-susceptible 10 24 - 1 2 10 47 (3.5)
Oxacillin-resistant 33 108 8 4 16 11 180 (13.5)
Enterococcus spp. 15 41 10 1 1 12 80 (6.0)
Streptococcus pneumoniae 64 84 113 - - 8 269 (20.2)
b-haemolytic streptococci 5 5 11 1 0 6 28 (2.1)
Viridans group streptococci 3 8 10 - 2 2 26 (1.8)
Haemophilus influenzae 34 41 54 - - - 129 (9.7)
Moraxella catarrhalis 9 10 33 - - 2 54 (4.0)
Neisseria meningitidis 1 - 7 - - - 8 (0.6)
Total (%) 264 (19.9) 573 (43.2) 377 (28.4) 15 (1.1) 26 (1.9) 69 (5.2) 1,326 (100.0)
a CoNS: Coagulase-negative staphylococci.
www.bjid.com.br
BJID 2005; 9 (October) 351Tigecycline Antimicrobial Activity in Latin America
Table 2. Antimicrobial activity of tigecycline in comparison to selected antimicrobial agents against 1,326 pathogen
isolates from Latin American medical centers (SENTRY Antimicrobial Surveillance Program, 2000-2002)
         MIC (µg/mL)a
Organism/antimicrobial agent
(no. tested) MIC50 MIC90 % susceptibleb
Staphylococcus aureus
Oxacillin-susceptible (288)
Tigecycline 0.25 0.5 100.0c
Tetracycline ≤4 >8 90.2
Erythromycin 0.25 >8 85.1
Ciprofloxacin 0.25 0.5 96.9
Quinupristin/Dalfopristin 0.25 0.5 100.0
Teicoplanin 0.5 1 99.7
Vancomycin 1 1 100.0
Linezolid 2 2 100.0
Oxacillin-resistant (217)
Tigecycline 0.25 0.5 100.0c
Tetracycline 8 >8 49.8
Erythromycin >8 >8 7.4
Ciprofloxacin >2 >2 4.6
Quinupristin/Dalfopristin 0.5 1 100.0
Teicoplanin 1 2 99.1
Vancomycin 1 1 100.0
Linezolid 2 2 100.0
CoNS
Oxacillin-susceptible (47)
Tigecycline 0.25 0.5 100.0c
Tetracycline 4 >8 76.6
Erythromycin 0.25 >8 74.4
Ciprofloxacin 0.25 0.25 95.3
Quinupristin/Dalfopristin 0.25 0.25 100.0
Teicoplanin 1 2 100.0
Vancomycin 1 2 100.0
Linezolid 1 1 100.0
Oxacillin-resistant (180)
Tigecycline 0.25 0.5 100.0c
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Tetracycline ≤4 >8 78.3
Erythromycin >8 >8 25.0
Ciprofloxacin 2 >2 47.8
Quinupristin/Dalfopristin 0.25 0.5 96.7
Teicoplanin 2 8 93.3
Vancomycin 1 2 100.0
Linezolid 1 2 100.0
Streptococcus pneumoniae (269)
Tigecycline 0.12 0.12 100.0c
Tetracycline ≤4 >8 83.6f
Erythromycin 0.25 1 87.7
Penicillin 0.03 2 72.9
Ceftriaxone 0.25 1 98.5e
Gatifloxacin 0.25 0.25 100.0
Quinupristin/Dalfopristin 0.25 0.5 100.0
Teicoplanin 0.12 0.12 100.0
Vancomycin 0.25 0.5 100.0
Linezolid 1 1 100.0
β-haemolytic streptococci (28)
Tigecycline 0.12 0.12 100.0c
Tetracycline >8 >8 46.4
Erythromycin 0.06 1 89.3
Penicillin 0.03 0.06 96.4
Gatifloxacin 0.25 0.5 96.4
Quinupristin/Dalfopristin 0.25 0.5 100.0
Teicoplanin 0.12 0.12 100.0
Vancomycin 0.25 0.5 100.0
Linezolid 1 1 100.0
Viridans group streptococci (26)
Tigecycline 0.12 0.25 100.0c
Tetracycline ≤4 >8 73.1
Erythromycin 0.06 2 65.4
Penicillin 0.12 2 69.2
Gatifloxacin 0.25 0.5 96.2
Quinupristin/Dalfopristin 0.5 1 92.3
Teicoplanin 0.12 0.12 100.0
Vancomycin 0.5 1 100.0
Linezolid 1 1 100.0
Enterococcus spp. (80)
Tigecycline 0.25 0.5 100.0c
Tetracycline >8 >8 27.5
Ampicillin ≤1 16 88.8
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Against  S. pneumoniae ,  t igecycline,
gatifloxacin, quinupristin/dalfopristin, vancomycin,
teicoplanin, and linezolid showed a susceptibility
rate of 100.0%. Four S. pneumoniae isolates were
not susceptible to ceftriaxone when non-meningitis
breakpoints were applied. Tigecycline (MIC50,
0.12 µg/mL) was as potent as teicoplanin (MIC50,
0.12 µg/mL) and two-fold more potent than
ceftriaxone (MIC50, 0.25 µg/mL), gatifloxacin
(MIC50, 0.25 µg/mL), and vancomycin (MIC50,
0.25 µg/mL) against S. pneumoniae. Tigecycline
was also highly active against S. pneumoniae,
including isolates resistant to penicillin and/or
tetracycline and/or erythromycin.
Tigecycline demonstrated excellent activity against
viridans group streptococci (MIC50/90, ≤ 0.12/0.25 µg/
mL) and β-haemolytic streptococci (MIC50/90, ≤ 0.12
µg/mL), whereas the corresponding MIC90 values for
tetracycline were > 8 µg/mL. Tigecycline, vancomycin,
teicoplanin, and linezolid (100.0% susceptible)
exhibited excellent coverage against these pathogens.
No cross-resistance between tigecycline and any of
the antimicrobial agents tested was observed among
streptococcal isolates.
Tigecycline Antimicrobial Activity in Latin America
Ciprofloxacin 1 >2 55.0
Quinupristin/Dalfopristin 8 8 13.8
Teicoplanin 0.25 1 92.5
Vancomycin 2 8 89.7
Linezolid 2 2 100.0
Haemophilus influenzae (129)
Tigecycline 0.25 0.25 100.0c
Tetracycline ≤4 ≤4 96.1f
Azithromycin 0.5 1 100.0
Clarithromycin 8 8 93.0
Ampicillin 0.5 1 82.2
Amoxicillin/Clavulanate 0.5 1 100.0
Ceftriaxone 0.008 0.016 100.0
Ciprofloxacin ≤0.03 ≤0.03 100.0
Chloramphenicol ≤2 ≤2 94.6
Moraxella catarrhalis (54)g
Tigecycline 0.12 0.5 100.0c
Tetracycline ≤4 ≤4 100.0
Azithromycin ≤0.12 ≤0.12 100.0
Clarithromycin ≤0.25 ≤0.25 100.0
Ampicillin ≤0.5 2 7.4
Amoxicillin/Clavulanate 0.12 0.25 100.0
Ceftriaxone 0.12 0.5 100.0
Ciprofloxacin ≤0.03 0.06 100.0
Chloramphenicol ≤2 ≤2 100.0
aMinimal inhibitory concentration determined by the broth microdilution technique [8]. bPercentage of
susceptibility calculated using the NCCLS breakpoints [9].cA susceptible breakpoint of ≤ 4 µg/mL was used
for comparative purposes only.dNo breakpoint has been established by the NCCLS.eBreakpoints for non-
meningitis were applied.fIncludes susceptible and intermediate. gBreakpoints for H. influenzae were used.
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Nearly 18.0% and 93.0% of the H. influenzae
and M. catarrhalis strains produced β-lactamase,
respectively. Haemophilus influenzae (MIC50/90,
0.25 µg/mL) and M. catarrhalis (MIC50/90, ≤ 0.12/
0.5 µg/mL) isolates were very susceptible to
tigecycline (100.0% susceptible), including β-
lactamase producing isolates. Only eight N.
meningitidis isolates were tested. Seven of them
were collected from a Chilean medical center. All of
the N. meningitidis showed tigecycline MIC at
concentrations ≤ 0.12 µg/mL. The tigecycline MIC
distribution among 1,326 pathogens tested is shown
in Table 3. The tigecycline MICs distributions were
not influenced by co-phenotypes of resistance, such
as oxacillin-resistance among staphylococci,
penicillin-resistance among S. pneumoniae or
glycopeptide resistance among Enterococcus spp.
The vast majority of isolates tested (1320 of 1326
or 99.5%) were inhibited at a concentration of ≤ 1
µg/mL of tigecycline.
Discussion
Tigecycline, a novel glycylcycline antibiotic, exhibits
strong activity against Gram-positive, Gram-negative,
aerobic, anaerobic, and atypical bacterial species,
including many resistant pathogens, i.e., vancomycin-
resistant enterococci, methicillin-resistant S. aureus
and penicillin-resistant S. pneumoniae [10-13]. In
addition, tigecycline has shown excellent activity
against most Gram-negative pathogens, including
Enterobacteriaceae ,  Acinetobacter spp.,
Stenotrophomonas maltophilia  [10,11],
Haemophilus influenzae, and Neisseria spp. [14].
Tigecycline’s expanded broad-spectrum activity is
further evidenced by its activity against Legionella
pneumophila [15], Chlamydia [16], rapidly growing
nontuberculosis mycobacteria [17] and anaerobes
[18]. On the other hand, tigecycline has demonstrated
limited activity against P. aeruginosa and Proteae
isolates [5,10,11].
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Table 3. Tigecycline MIC distribution among 1,326 pathogens from the SENTRY Antimicrobial Surveillance
Program (Latin America, 2000-2002)
Organism (n tested) No. of isolates (cumulative %) inhibited at MIC (µg/mL)
≤ 0.12 0.25 0.5 1 2
Staphylococcus aureus
Oxacillin-susceptible (288) 111 (38.5) 94 (71.2) 81 (99.3) 2 (100.0) -
Oxacillin-resistant (217) 63 (29.1) 100 (75.1) 51 (98.6) 2 (99.5) 1 (100.0)
CoNSa
Oxacillin-susceptible (47) 15 (31.9) 15 (63.8) 14 (93.6) 3 (100.0) -
Oxacillin-resistant (180) 41 (22.8) 55 (53.3) 70 (92.2) 13 (99.4) 1 (100.0)
Streptococcus pneumoniae (269) 268 (99.6) 1 (100.0) - - -
Haemophilus influenzae (129) 8 (6.2) 28 (27.9) 72 (83.7) 17 (96.9) 4 (100.0)
Enterococcus spp. (80) 37 (43.3) 23 (75.0) 20 (100.0) - -
Moraxella catarrhalis (54) 31 (57.4) 17 (88.9) 6 (100.0) - -
β-haemolytic streptococci (28) 28 (100.0) - - - -
Viridans group streptococci (26) 23 (88.5) 1 (92.3) 2 (100.0) - -
Neisseria meningitidis (8) 8 (100) - - - -
a.CoNS: Coagulase-negative staphylococci.
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The results of two randomized trials assessing the
clinical efficacy of tigecycline were recently released
[19]. The studies evaluated tigecycline versus
vancomycin plus aztreonam to treat complicated skin
and skin structure infections (cSSSI), and tigecycline
versus imipenem plus cilastatin to treat complicated
intrabdominal infections (cIAI). In the first trial, 274
patients received tigecycline and 269 received
vancomycin plus aztreonam. The clinical cure rate of
cSSSI between the two groups was not statistically
different (84.3% versus 86.9%, respectively). The
cIAI trial comprised 404 and 413 patients treated with
tigecycline and imipenem plus cilastatin, respectively.
Clinical cure was again not statistically distinct (86.6%
of the tigecycline group and in 84.4% of those on
combination therapy). In both trials, the most frequently
reported adverse events for patients on tigecycline were
nausea and vomiting [19].
Our results agree with previous in vitro studies
[5,10-14] and emphasize that tigecycline has excellent
activity and spectrum against Gram-positive bacteria,
including multi-drug resistant strains, and bacterial
pathogens causing community-acquired respiratory
tract infections isolated from patients hospitalized in
Latin American medical centers. These results,
associated with the tigecycline clinical efficacy data
already published, suggest that tigecycline may have
an important role in the treatment of severely ill patients,
especially in an environment with high antimicrobial
resistance levels such as the Latin American region.
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